Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.

International journal of molecular sciences - 5 Apr 2026

Park Nuri, Cho Yejin, Zheng Hong-Mei, Ryu Woo Kyung, Jung Kyung Hee, Lim Jun Hyeok

Abstract excerpt

Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) has historically been regarded as a therapeutically uniform entity, characterized by marked sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and limited responsiveness to immune-checkpoint inhibitors (ICIs). However, accumulating clinical and translational data suggest heterogeneity within EGFR-mutant NSCLCs. In particular,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41977474
DOI: 10.3390/ijms27073294
PMCID: PMC13073372

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.PMID 41977474Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read ↗

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.Semantic proximity Read ↗

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.Semantic proximity Read ↗

PD-1/PD-L1 Axis in Lung Cancer.Semantic proximity Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.